Canonical mutations in IDH1 and IDH2 produce high levels of the R-enantiomer of 2-hydroxyglutarate (R-2HG), which is a competitive inhibitor of α-ketoglutarate (αKG)-dependent enzymes and a putative oncometabolite. Mutant IDH1 collaborates with HoxA9 to induce monocytic leukemia in vivo. We used two mouse models and a patient-derived acute myeloid leukemia xenotransplantation (PDX) model to evaluate the in vivo transforming potential of R-2HG, S-2HG and αKG independent of the mutant IDH1 protein. We show that R-2HG, but not S-2HG or αKG, is an oncometabolite in vivo that does not require the mutant IDH1 protein to induce hyperleukocytosis and to accelerate the onset of murine and human leukemia. Thus, circulating R-2HG acts in a paracrine manner and can drive the expansion of many different leukemic and preleukemic clones that may express wild-type IDH1, and therefore can be a driver of clonal evolution and diversity. In addition, we show that the mutant IDH1 protein is a stronger oncogene than R-2HG alone when comparable intracellular R-2HG levels are achieved. We therefore propose R-2HG-independent oncogenic functions of mutant IDH1 that may need to be targeted in addition to R-2HG production to exploit the full therapeutic potential of IDH1 inhibition.
INTRODUCTION
Mutations in the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) are frequently found in several tumors, including acute myeloid leukemia (AML), glioma, chondrosarcoma and intrahepatic cholangiocarcinoma. [1] [2] [3] [4] Mutations in IDH1 and IDH2 occur almost exclusively at conserved amino acids, [5] [6] [7] which affect the active sites where IDH1/2 substrates isocitrate and NADP + (nicotinamide adenine dinucleotide phosphate) bind. [8] [9] [10] The conversion of isocitrate to α-ketoglutarate (αKG) is impaired in the mutant (mut) proteins, resulting in reduced production of αKG and NADPH. 11 Furthermore, IDH1mut proteins gain a neomorphic ability to convert αKG to the R-enantiomer of 2-hydroxyglutarate (R-2HG, also known as D-2HG). [8] [9] [10] Almost all patients with canonical IDH1/2 mutations express high levels of intracellular R-2HG, 8 whereas an increase of the S-enantiomer of 2HG has never been described in AML, glioma, chondrosarcoma or intrahepatic cholangiocarcinoma patients. Although αKG is a cofactor for many dioxygenases 12 involved in diverse processes such as hypoxic response, nucleic acid repair and modification, fatty acid metabolism and chromatin modification, 13 it was shown that 2HG is an inhibitor of these dioxygenases.
14 Surprisingly, S-2HG inhibits most dioxygenases more potently than R-2HG. [14] [15] [16] Therefore, the pathophysiologic role of R-2HG remains unclear. 17 As was shown previously, mutant IDH1 is not sufficient to cause leukemia as a single oncogenic hit. 18, 19 We found that mutant IDH1 is frequently associated with high expression of HOXA and HOXB cluster genes in AML patients and coexpression of mutant IDH1 with HoxA9 in mouse bone marrow cells induced a rapid monocytic leukemia in mice. 19 Whether oncometabolites (e.g. R-2HG and/or S-2HG) have a causative function in leukemogenesis/carcinogenesis or rather are only biomarkers for oncogenic IDH remains to be demonstrated. To test this, we performed daily administration of R-2HG, S-2HG and αKG in vivo in the HoxA9 mouse model and additional models containing only wild-type (wt) IDH1.
MATERIALS AND METHODS

Retroviral vectors and infection of primary bone marrow cells
Retroviral vectors MSCV-HoxA9-PGKneo, pSF91-IRES-eGFP, pSF91-IDH1mut-IRES-eGFP, pSF91-IDH1wt-IRES-eGFP have been described previously, 19 and MSCV-MLL-AF9-IRES-eGFP was a kind gift from Dr Florian Kuchenbauer (University Hospital Ulm, Ulm, Germany). Primary mouse bone marrow cells from C57BL/6 J mice were transduced with helper-free recombinant retrovirus as described previously. 19 In brief, bone marrow cells were harvested from 5-fluorouracil-treated mice (Medac, Hamburg, Germany), and were infected first by cocultivation with a HoxA9 viral producer cell line followed by either control (CTL) vector or IDH1wt or IDH1mut viral producer GP+E86 cells. Alternatively, prestimulated bone marrow cells were transduced with MLL-AF9. Cells were then sorted for GFP (green fluorescent protein) expression and maintained in 6 ng/ml murine interleukin-3, 10 ng/ml human interleukin-6 and 20 ng/ml murine stem cell factor (Peprotech, Hamburg, Germany).
were purchased from the animal facility of Hannover Medical School (Hannover, Germany) and kept in pathogen-free conditions at the central animal laboratory of Hannover Medical School. Neither randomization nor blinding was used as all animal experiments were performed with homogeneous strains, at the same age and in mice with similar engraftment.
Equal numbers of GFP-expressing, sorted bone marrow cells from C57BL/6 J mice were injected intravenously in lethally irradiated syngeneic recipient mice that were irradiated with 800 cGy, accompanied by a lifesparing dose of 1 × 10 5 freshly isolated bone marrow cells from syngeneic mice. NSG mice were irradiated with 3 Gy and transplanted with IDH1wt, NPM1-mutated human AML patient cells (patient-derived AML xenotransplantation (PDX) model). After injection of one million cells, the mice developed leukemia within 90 days with 495% chimerism, which could engraft secondary recipients. Untransplanted C57BL/6 J mice, and mice receiving transplants of HoxA9+CTL or MLL-AF9-transduced bone marrow cells or cells from an AML patient (PDX-AML), were treated once daily with R-2HG disodium salt (H8378; Sigma-Aldrich, Steinheim, Germany), S-2HG disodium salt (90970; Sigma-Aldrich) or α-KG (K-1128; Sigma-Aldrich) intraperitoneally at a dose of 1 mg per mouse or 100 μl of phosphatebuffered saline (PBS).
For secondary transplantation, one million cells from the bone marrow of primary transplanted and R-2HG-, S-2HG-, α-KG-or PBS-treated mice were injected intravenously in lethally irradiated syngeneic recipient mice and subsequently treated with the corresponding metabolite as described above. Engraftment was monitored by tail vein bleeds and FACS (fluorescence-activated cell sorting) analysis of GFP-expressing cells every 4 weeks as described previously. 19, 20 Blood counts with differential white blood cell analysis were performed using an ABC Vet Automated Blood counter (Scil Animal Care Company GmbH, Viernheim, Germany). Lineage distribution was determined by FACS analysis (FACS Calibur, Becton Dickinson, Heidelberg, Germany) as described previously. 21 Antibodies for FACS staining and morphologic analysis Monoclonal antibodies used for lineage staining were as follows: Gr1-PE (clone-RB6-8CS), B220-PE (RA3-6B2), Sca-1-PE (D7), cKit-APC (2B8) and CD45-FITC (HI30) from BD Biosciences (Heidelberg, Germany); CD11b-APC (M1/70) and F4/80-PE (BM8) from eBioscience (Frankfurt, Germany). Antibodies used for the lineage cocktail were as folllows: PerCP Cy5.5-labeled CD4 (GK1.5) and Ter1AZ9 (Ter-119) from BioLegend (Fell, Germany); B220 (RA3-6B2) and CD3 (145-2C11) from BD Biosciences; and Gr1 (RB6-8C5C), CD8 (53-6.7), IL7R (A7R34) and CD11b (M1/70) from eBioscience. Antibodies used for SLAM HSC staining were CD48-APC (HM48-1) and CD150-PECy7 (TC-15-12F12.2) from BioLegend and CD244-PE (2B4) from eBioscience. Antibodies used for progenitor staining were CD16/32-PE (93), CD34-biotin (RAM34) and Sca1-PECy7 (D7) from eBioscience, and cKit-APC (2B8) and streptavidin-APC-Cy7 from BD Biosciences. Cytospin preparations were stained with Wright-Giemsa stain. The morphology of bone marrow was assessed with an Olympus BX51 (Olympus, Tokyo, Japan) microscope and a x40/0.75 numerical aperture objective, or a x100/1.3 numerical aperture objective with Zeiss immersol medium (Zeiss, Jena, Germany). OlympusXC50 (Olympus) and analySIS software (Soft Imaging System, Stuttgart, Germany) were used to capture images.
Patient samples
Diagnostic bone marrow, peripheral blood or serum samples collected from AML patients registered for the multicenter treatment trial AML-SHG 01/99 or 02/95 were analyzed for mutations in IDH1 and 2HG levels as described previously. 6, 19 Five million cells were used per sample for 2HG quantification. Written informed consent was obtained according to the Declaration of Helsinki, and the study was approved by the institutional review board of Hannover Medical School.
2HG quantification
Bone marrow cells or serum were isolated from mice either transplanted with IDH1mut-expressing cells or treated with metabolites for 4 weeks. To determine intracellular R-and S-2HG levels, either 10 μl serum was directly used or five million cells were sonicated for 10 min at intervals of 30 s on, 30 s off at 4°C using the Bioruptor (Diagenode, Liege, Belgium) followed by two rounds of freeze-thaw cycles. All analyses were performed on an AB Sciex 4000 Q-trap triple quadruple mass spectrometer (Applied Biosystems, Darmstadt, Germany). LC was performed on a Waters Acquity UPLC BEH C 18 analytical column (100 × 2.1 mm 2 (i.d.)), and 1.7-μm bead size with water-acetonitrile (96.5:3.5 by volume) containing 125 mg/l ammonium formate (pH adjusted to 3.6 by the addition of formic acid) as mobile phase as described. 22 Immunoblotting Cellular lysates were prepared and immunoblotting was performed as described previously. 19, 20 Primary antibodies used were polyclonal goat anti-HoxA9 (N-20) from Santa Cruz Biotechnology (Heidelberg, Germany) and monoclonal mouse-anti-β-actin (AC-15) from Sigma-Aldrich (Hannover, Germany). Secondary horseradish peroxidase-conjugated antibodies used were bovine-anti-goat (Santa Cruz Biotechnology) and goat-antimouse (Beckman Coulter, Fullerton, CA, USA).
Cell cycle analysis
For cell cycle analysis, mice were injected intraperitoneally with 100 μl bromodeoxyuridine (1 mM) at 36, 24 and 12 h before harvest of cells. A total of 1 × 10 7 bone marrow cells per mouse were stained with antibodies specific for cell surface antigens, followed by permeabilization, fixation and staining with an anti-bromodeoxyuridine antibody according to the manufacturer's protocol (BD Biosciences; cat. no. 559619).
Gene expression profiling GFP-positive cells were sorted from mouse bone marrow cells 4 weeks after transplantation/start of treatment and were hybridized to Affymetrix Mouse Genome 430 2.0 GeneChips (High Wycombe, UK) as described previously. 19 Data were analyzed using R (https://www.r-project.org/) and Bioconductor (https://www.bioconductor.org/). Microarray quality was assessed using the arrayQualityMetrics package. 23 Arrays were background corrected, normalized and summarized using RMA. 24 For unsupervised hierarchical clustering, the expression set was filtered based on a log 2 (interquartile range). 25 LIMMA was used to detect differentially expressed probe sets applying Benjamini-Hochberg step-up multiple testing correction considering false discovery rate of o0.05 significant. 26 Genome-wide gene expression data from R-2HG-treated HoxA9 CTL, IDH1wt and IDH1mut cells were used for gene set enrichment analysis. 27 The Broad Institute GSEA software package was used for gene set enrichment analysis using gene ontology gene sets from the Molecular Signatures Database (http://www.broad.mit.edu/gsea/msigdb/). Gene expression profiling data can be found at the gene expression omnibus database under accession number GSE77594.
Quantitative RT-PCR RNA was extracted and reverse transcribed as described previously. 28 Quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) was performed as previously described using SYBR green (Life Technologies, Darmstadt, Germany) for quantification of double-stranded DNA on a StepOne Plus cycler (Life Technologies, Darmstadt, Germany). 29 Relative expression was determined with the 2 − ΔΔCT method, 30 and the housekeeping gene transcript Abl1 was used to normalize the results.
Reduced representation bisulfite sequencing and analysis of methylome data (RRBS-Seq)
DNA from HoxA9 cells expressing CTL vector, IDH1wt or IDH1mut proteins was used for reduced representation bisulfite sequencing (RRBS) library preparation using a published protocol with minor modifications. 31 BSMAP aligner 32 and Lister protocol was used for data analysis. 33 Detailed methods for RRBS and its analysis are provided in the data supplement. RRBS data can be found at the gene expression omnibus database under accession number GSE77828.
Statistical analysis
Pairwise comparisons were performed by Student's t-test for continuous variables and by χ 2 test for categorical variables. The two-sided level of significance was set at P o 0.05. Statistical analyses were performed with Microsoft Excel (Microsoft, Munich, Germany) or GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). Graphical representation was prepared using Adobe illustrator CS5.1 (Adobe systems GmbH, Munich, Germany).
The size of animal cohorts was based on our previous study. Figure S1 ), selected for GFP expression and transplanted in lethally irradiated mice (Supplementary Figure S2) . We treated these mice once daily with intraperitoneal injections of 1 mg of R-2HG, S-2HG, αKG or 100 μl of PBS. As a control, HoxA9+IDH1mut-expressing cells were transplanted in recipient mice and were kept without further treatment. At 4 weeks some mice were killed to measure intracellular 2HG levels in bone marrow cells. The ratio of the R-to S-enantiomer is the most reliable measure of R-2HG in cells as it is independent of cell number. This ratio was similar in R-2HG-treated mice as in primary human AML cells (Figure 1a and Supplementary Table S1 ) and slightly higher in serum of mice treated with R-2HG compared with that in serum of AML patients (Figure 1b) . The higher concentration in the serum of R-2HG-treated mice is not surprising as R-2HG is provided from the extracellular space, whereas the origin of R-2HG in AML patients is intracellular. S-2HG was increased in cells and serum of S-2HG-treated mice (Supplementary Figure S3 and Supplementary  Table S1 ).
Monitoring of leukemic onset showed that R-2HG-treated mice had significantly higher engraftment levels in peripheral blood (Figure 1c) , developed striking leucocytosis from 12 weeks onwards (Figure 2a ) and had declining hemoglobin and platelets compared with S-2HG-, αKG-or PBS-treated mice ( Supplementary  Figures S4A and S4B) . # All mice are dead; *Po 0.05; **P o0.01.
R-2HG not S-2HG induces leukemia in vivo
Peripheral blood from R-2HG-treated mice revealed significantly more immature CD11b+Gr1 − and less mature CD11b+Gr1+ myeloid cells at 12 and 16 weeks after treatment than S-2HG-, αKG-and PBS-treated mice (Figure 2b and Supplementary Figure S4C) . Interestingly, the R-2HG-treated mice died significantly earlier with a median latency of 137 days post transplantation from monocytic leukemia than mice treated with S-2HG, αKG and PBS (median latency of 223, 202 and 184 days, respectively; P o0.001, Figure 2c ; Supplementary Figure S4D shows high engraftment of HoxA9 cells in bone marrow, spleen and peripheral blood at death; Supplementary Figure S4E shows monoblastic cells in bone marrow). As expected, these cells were readily transplantable in secondary animals ( Supplementary  Figures S5A and S5B ).
R-2HG, but not S-2HG, accelerates leukemic onset of MLL-AF9 leukemia in vivo
To investigate whether R-2HG is an oncometabolite in vivo independent of HoxA9, we next treated mice transplanted with MLL-AF9-transduced mouse bone marrow cells. R-2HG-treated mice had a high R-2HG/S-2HG ratio in serum (Figure 3a) . Similarly, S-2HG-treated mice had a high S-2HG/R-2HG ratio in serum (Supplementary Figure S6A) . R-2HG treatment induced the same effects as in the HoxA9 model with severe leukocytosis and thrombocytopenia and shorter disease latency compared with S-2HG-or PBS-treated mice (Figure 3b and Supplementary Figures  S6B and 3C ), whereas hemoglobin levels were similar between the treatment groups (Supplementary Figure S6C) . Peripheral blood from R-2HG-treated mice had significantly more immature F4/80 +CD11b − and less mature F4/80+CD11b+ cells than S-2HG-and PBS-treated mice at 4 weeks after treatment (Supplementary Figure S6D) . This confirms the oncometabolic potential of R-2HG in an independent murine leukemia model.
R-2HG, but not S-2HG, accelerates primary human IDH1wt AML in vivo
We next confirmed the oncometabolic role of R-2HG in a PDX model of human AML. This PDX model was established from an IDH1wt/NPM1mut patient. R-2HG-treated mice had a high R-2HG/ S-2HG ratio in serum (Figure 4a ). S-2HG-treated mice had a high S-2HG/R-2HG ratio in serum (Supplementary Figure S7A) . Again, R-2HG treatment induced significantly higher engraftment of human CD45+ cells and white blood cells at 12 weeks and significantly lower platelet counts at 4, 8 and 12 weeks compared Figure S7D) . R-2HG-treated mice died significantly earlier than S-2HG-and PBS-treated mice (Figure 4c) , confirming the leukemogenic function of R-2HG in primary human cells in vivo.
IDH1mut has additional oncogenic potency and function beyond R-2HG A question of current investigation is whether R-2HG alone is responsible for the oncogenic effects of IDH1mut and IDH2mut or if the mutant protein contributes additional oncogenic functions. Both cohorts, HoxA9+IDH1mut and HoxA9 treated with R-2HG, developed monocytic leukemia, albeit with different kinetics. The Hoxa9+IDH1mut mice died with a median latency of 83 days, whereas the R-2HG cohort died with a median latency of 137 days post transplantation (P o 0.001; Figure 2c ). Engraftment in peripheral blood was significantly higher in IDH1mut compared with that in R-2HG-treated mice at 8 and 12 weeks (Figure 1c ). In addition, severe leukocytosis, anemia and thrombocytopenia developed earlier in IDH1mut mice than in R-2HG-treated mice (Figure 2a and Supplementary Figures S4A and S4B) . No difference was seen for the frequency of cKit+/Sca1 − cells between the treatment groups and IDH1mut (Supplementary Figure S8) .
Therefore, we examined whether the faster disease kinetics of IDH1mut compared with R-2HG was due to a lower concentration of R-2HG in the treated mice, and would be overcome if the R-2HG dose was increased. Mice transplanted with HoxA9-expressing cells were treated with 0.2, 1 and 5 mg of R-2HG. We observed a dose-dependent increase of R-2HG in bone marrow cells of treated mice, whereas the dose of 5 mg R-2HG per day even slightly exceeded R-2HG of cells expressing IDH1mut (Figure 5a ). Despite unequal intracellular R-2HG levels, mice treated with 1 or 5 mg of R-2HG had similar engraftment levels and died with an identical latency, whereas IDH1mut mice died significantly earlier and lastly mice treated with 0.2 mg R-2HG died with the same latency as the PBS cohort (Figures 5b and c) . Thus, we have established non-oncogenic R-2HG levels and identified a ceiling effect for R-2HG, beyond which no further oncogenicity is seen. The full oncogenic potential of R-2HG was seen at a dose of 1 mg per day R-2HG, corresponding to an R-2HG/S-2HG ratio of 200 and an R-2HG concentration of 300 μM. Strikingly, at comparable intracellular R-2HG levels IDH1mut mice died significantly earlier than R-2HG-treated mice strongly suggesting oncogenic functions of IDH1mut beyond R-2HG.
R-2HG alone is insufficient to induce myeloproliferation or leukemia in vivo To assess whether R-2HG alone was sufficient as a single hit to induce myeloproliferation or leukemia, normal C57BL/6 mice (without HoxA9) were treated with R-2HG, S-2HG or PBS for 8 months. Three mice were killed at 4 weeks of treatment and 2HG levels were quantified in bone marrow cells. High levels of R-2HG were measured in R-2HG-treated mice, whereas high levels of S-2HG were measured in S-2HG-treated mice ( Supplementary  Figures S9A and S9B ). No differences were observed for survival (Supplementary Figure S9C) , spleen weight (Supplementary Figure S9D) , blood counts (Supplementary Figures S9E-S9G ) and immunophenotype in peripheral blood (Supplementary Figure S9H) and bone marrow (Supplementary Figure S10) after 8 months of treatment. We found comparable frequencies of stem and progenitor cells (lin − cKit+Sca1+, CMP, GMP and MEP) in bone marrow between treatment and control groups at 4 months of treatment (Supplementary Figure S9I) and a similar cell cycle distribution between these cell types (Supplementary Figure S11) . These data show that the metabolite R-2HG, but not S-2HG, has oncogenic potential in vivo in cooperation with HoxA9 such as the IDH1mut protein but is insufficient to induce leukemia by itself.
IDH1mut and R-2HG have similar and distinct effects on gene expression and DNA methylation To identify similarities and potential differences between IDH1-mut-and R-2HG-treated HoxA9 cells, we compared gene expression and DNA methylation profiles of bone marrow cells harvested 4 weeks after transplantation/treatment. Based on the gene expression data, R-2HG-treated cells clustered with IDH1mut cells, whereas IDH1wt cells clustered with HoxA9 control cells (Figure 6a and Supplementary Table S2) . However, many genes that were overexpressed in IDH1mut cells were not upregulated in R-2HG-treated cells and principal component analysis showed that Figure S12) . By gene set enrichment analysis using gene ontology gene sets, we found that 16% of the enriched gene ontology terms were shared between IDH1mut and R-2HG-treated cells (Figure 6b and Supplementary  Table S3 ). We selected genes that had a role in myeloid differentiation and were downregulated in R-2HG-treated and IDH1mut cells, and validated their expression by real-time RT-PCR (Figure 6c ). Expression of Myadm and Ccl6 were most strongly downregulated, confirming a differentiation inhibiting effect of R-2HG.
Next, we compared DNA methylation in IDH1wt-, IDHmut-and R-2HG-treated cells by reduced representation bisulfite sequencing using bone marrow cells harvested 4 weeks after transplantation/treatment that were sorted for transgene expression (Supplementary Figure S13) . The differentially methylated regions between R-2HG-treated cells and IDH1wt cells were well represented in IDH1mut cells (IDH1mut cells cluster together with R-2HG-treated cells; Figure 7a and Supplementary Table S4) . However, differentially methylated regions between IDH1mut and IDH1wt cells were not well represented in R-2HG-treated cells and these cells clustered with IDH1wt and not IDH1mut cells (Figure 7b and Supplementary Table S5 ). The higher number of hyper-and hypomethylated regions in IDH1mut cells compared with R-2HG-treated cells as shown in Figure 7c , supports an additional function of the mutant protein on transcriptional regulation and DNA methylation beyond the function of the metabolite R-2HG and may explain the earlier disease onset of IDH1mut cells compared with R-2HG-treated cells.
DISCUSSION
We show that R-2HG, but not S-2HG, promotes leukemogenesis in murine and human pretransformed cells in vivo. Previously, it has been shown that R-2HG can recapitulate properties of IDH1mut in vitro such as enhanced proliferation, blocked differentiation and histone and DNA methylation, 14, 18, 34, 35 but the unique oncogenic potential of R-2HG compared with S-2HG had not been evaluated in vivo. It has been puzzling why all 2HG-producing tumors expressed R-2HG but not S-2HG. Our findings offer an explanation to this phenomenon as R-2HG treatment provided a competitive advantage to immortalized myeloid progenitor cells in vivo. Our findings also show that R-2HG not only acts in an autocrine manner on the cells that contain a IDH1-mutated protein and therefore produce R-2HG but also in a paracrine manner on cells that are susceptible to transformation by R-2HG. This suggests that high R-2HG levels also affect the growth of IDH1wt clones that may be present in IDH1mut tumors and may enhance clonal diversity and evolution.
2HG inhibits many αKG-dependent dioxygenases, many of which are more strongly inhibited by S-2HG than by R-2HG. [14] [15] [16] Our data suggest that dioxygenases that are equally or more efficiently inhibited by R-2HG than S-2HG are most relevant for leukemogenesis such as the H3K4 and H3K36 demethylases KDM4A and KDM4C and the mitochondrial electron transport component cytochrome c oxidase. 15, 34, 36 On the other hand, enzymes that are more potently inhibited by S-2HG than by R-2HG, such as TET2 or BBOX1, 14, 15 seem to have a minor role in IDH1-induced transformation. In contrast to R-2HG being oncogenic, Losman et al. 35 have postulated that S-2HG can antagonize the transforming effects of TET2 knockdown in TF1 cells, thus assigning a tumor-suppressive role to S-2HG. However, in the context of HoxA9, MLL-AF9 and primary human AML cells, S-2HG treatment neither accelerated nor delayed disease onset in our in vivo model, suggesting that S-2HG is neutral towards leukemogenesis.
Our data confirm previous observations that IDH1mut requires a collaborating oncogene to induce leukemia or glioma, 18, 19, 37 as R-2HG treatment had no measurable effect in normal mice during the observation period of 8 months. The low oncogenic potential of R-2HG in normal tissues is further supported by the observation that children with hydroxyglutaric aciduria never develop tumors or leukemia. 38 Hydroxyglutaric aciduria is a metabolic disorder, which presents with neurologic symptoms such as seizures, developmental retardation, ataxia and others in young children. 38 The limited survival of these patients may not provide the time frame that is required to develop mutations that can synergize with high R-2HG levels.
The IDH1mut protein induced leukemia more rapidly than R-2HG in HoxA9 cells, even at comparable doses of R-2HG. We show that the R-2HG-induced gene expression and methylation changes are mostly preserved in IDH1mut cells, whereas the IDH1mut protein induces broader gene expression and methylation changes. Gene ontology gene sets that were shared between IDH1mut and R-2HG fell into the category of signaling, suggesting that R-2HG has a critical effect on signal transduction. In R-2HG-treated cells, gene sets related to ion transport were uniquely enriched, whereas transcriptional regulation was uniquely enriched in IDH1mut cells. This suggests that IDH1mut contributes to leukemogenesis with additional mechanisms than R-2HG production and that full inhibition of IDH1mut may require more than just inhibition of R-2HG production.
In summary, we show that R-2HG, but not S-2HG, is an oncometabolite that does not require the IDH1mut protein to induce hyperleukocytosis and to accelerate disease onset in vivo. Thus, circulating R-2HG acts in a paracrine fashion and can drive the expansion of many different leukemic and preleukemic clones that may even express IDH1wt, and therefore can be a source of clonal evolution and diversity. 
